|
Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD). |
|
|
Employment - Atara Biotherapeutics |
Travel, Accommodations, Expenses - Atara Biotherapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Atara Biotherapeutics |
Research Funding - Atara Biotherapeutics |
|
|
Stock and Other Ownership Interests - Atara Biotherapeutics |
Honoraria - Atara Biotherapeutics |
Consulting or Advisory Role - Atara Biotherapeutics |
Research Funding - Atara Biotherapeutics |
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics |
Travel, Accommodations, Expenses - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
No Relationships to Disclose |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics |
|
|
Employment - Atara Biotherapeutics |
Stock and Other Ownership Interests - Atara Biotherapeutics; bluebird bio; GE Healthcare; Kite, a Gilead company; Pfizer |
Patents, Royalties, Other Intellectual Property - Patent pending for a use of cytotoxic T lymphocytes (Inst) |